Lauria Claeys1, Silvia Storoni2, Marelise Eekhoff2, Mariet Elting1, Lisanne Wisse1, Gerard Pals1, Nathalie Bravenboer3, Alessandra Maugeri1, Dimitra Micha4. 1. Department of Clinical Genetics, Amsterdam UMC, Amsterdam Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 2. Department of Internal Medicine Section Endocrinology, Amsterdam UMC, Amsterdam Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 3. Department of Clinical Chemistry, Amsterdam /UMC, Amsterdam Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 4. Department of Clinical Genetics, Amsterdam UMC, Amsterdam Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. d.micha@amsterdamumc.nl.
Abstract
Osteogenesis Imperfecta (OI) comprises a heterogeneous group of patients who share bone fragility and deformities as the main characteristics, albeit with different degrees of severity. Phenotypic variation also exists in other connective tissue aspects of the disease, complicating disease classification and disease course prediction. Although collagen type I defects are long established as the primary cause of the bone pathology, we are still far from comprehending the complete mechanism. In the last years, the advent of next generation sequencing has triggered the discovery of many new genetic causes for OI, helping to draw its molecular landscape. It has become clear that, in addition to collagen type I genes, OI can be caused by multiple proteins connected to different parts of collagen biosynthesis. The production of collagen entails a complex process, starting from the production of the collagen Iα1 and collagen Iα2 chains in the endoplasmic reticulum, during and after which procollagen is subjected to a plethora of posttranslational modifications by chaperones. After reaching the Golgi organelle, procollagen is destined to the extracellular matrix where it forms collagen fibrils. Recently discovered mutations in components of the retrograde transport of chaperones highlight its emerging role as critical contributor of OI development. This review offers an overview of collagen regulation in the context of recent gene discoveries, emphasizing the significance of transport disruptions in the OI mechanism. We aim to motivate exploration of skeletal fragility in OI from the perspective of these pathways to identify regulatory points which can hint to therapeutic targets.
Osteogenesis Imperfecta (OI) comprises a hetn class="Gene">erogeneous group of patients who share bone fragility and deformities as the main characteristics, albeit with different degrees of severity. Phenotypic variation also exists in other connective tissue aspects of the disease, complicating disease classification and disease course prediction. Although collagen type I defects are long established as the primary cause of the bone pathology, we are still far from comprehending the complete mechanism. In the last years, the advent of next generation sequencing has triggered the discovery of many new genetic causes for OI, helping to draw its molecular landscape. It has become clear that, in addition to collagen type I genes, OI can be caused by multiple proteins connected to different parts of collagen biosynthesis. The production of collagen entails a complex process, starting from the production of the collagen Iα1 and collagen Iα2 chains in the endoplasmic reticulum, during and after which procollagen is subjected to a plethora of posttranslational modifications by chaperones. After reaching the Golgi organelle, procollagen is destined to the extracellular matrix where it forms collagen fibrils. Recently discovered mutations in components of the retrograde transport of chaperones highlight its emerging role as critical contributor of OI development. This review offers an overview of collagen regulation in the context of recent gene discoveries, emphasizing the significance of transport disruptions in the OI mechanism. We aim to motivate exploration of skeletal fragility in OI from the perspective of these pathways to identify regulatory points which can hint to therapeutic targets.
Authors: Yasemin Alanay; Hrispima Avaygan; Natalia Camacho; G Eda Utine; Koray Boduroglu; Dilek Aktas; Mehmet Alikasifoglu; Ergul Tuncbilek; Diclehan Orhan; Filiz Tiker Bakar; Bernard Zabel; Andrea Superti-Furga; Leena Bruckner-Tuderman; Cindy J R Curry; Shawna Pyott; Peter H Byers; David R Eyre; Dustin Baldridge; Brendan Lee; Amy E Merrill; Elaine C Davis; Daniel H Cohn; Nurten Akarsu; Deborah Krakow Journal: Am J Hum Genet Date: 2010-04-01 Impact factor: 11.025
Authors: Hamoun Ashournia; Frank Ted Johansen; Lars Folkestad; Axel C P Diederichsen; Kim Brixen Journal: Int J Cardiol Date: 2015-06-14 Impact factor: 4.164
Authors: Aileen M Barnes; Wayne A Cabral; MaryAnn Weis; Elena Makareeva; Edward L Mertz; Sergey Leikin; David Eyre; Carlos Trujillo; Joan C Marini Journal: Hum Mutat Date: 2012-07-16 Impact factor: 4.878
Authors: Dustin Baldridge; Ulrike Schwarze; Roy Morello; Jennifer Lennington; Terry K Bertin; James M Pace; Melanie G Pepin; Maryann Weis; David R Eyre; Jennifer Walsh; Deborah Lambert; Andrew Green; Haynes Robinson; Melonie Michelson; Gunnar Houge; Carl Lindman; Judith Martin; Jewell Ward; Emmanuelle Lemyre; John J Mitchell; Deborah Krakow; David L Rimoin; Daniel H Cohn; Peter H Byers; Brendan Lee Journal: Hum Mutat Date: 2008-12 Impact factor: 4.878
Authors: Aileen M Barnes; Erin M Carter; Wayne A Cabral; MaryAnn Weis; Weizhong Chang; Elena Makareeva; Sergey Leikin; Charles N Rotimi; David R Eyre; Cathleen L Raggio; Joan C Marini Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: M Balasubramanian; J Hurst; S Brown; N J Bishop; P Arundel; C DeVile; R C Pollitt; L Crooks; D Longman; J F Caceres; F Shackley; S Connolly; J H Payne; A C Offiah; D Hughes; M J Parker; W Hide; T M Skerry Journal: Bone Date: 2016-10-24 Impact factor: 4.398
Authors: Silvia Ciancia; Rick R van Rijn; Wolfgang Högler; Natasha M Appelman-Dijkstra; Annemieke M Boot; Theo C J Sas; Judith S Renes Journal: Eur J Pediatr Date: 2022-04-06 Impact factor: 3.860